Effect of astragaloside IV against rat myocardial cell apoptosis induced by oxidative stress via mitochondrial ATP-sensitive potassium channels

FENG-YING GUAN¹, SHI-JIE YANG¹, JINXIANG LIU² and SI-RUI YANG²

¹Department of Pharmacology, College of Basic Medical Sciences, Jilin University; ²Department of Pediatric Cardiology, Institute of Pediatrics, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Received May 9, 2014; Accepted February 13, 2015

DOI: 10.3892/mmr.2015.3400

Abstract. Astragaloside is one of the most common traditional Chinese medicines and is derived from Astragalus membranaceus. Astragaloside IV (AsIV) is a monomer located in an extract of astragaloside. The current study investigated the protective effects of AsIV against hydrogen peroxide (H₂O₂)-induced injury in cardiocytes and elucidated the mechanisms responsible for this protective effect. Cultured neonatal rat cardiocytes were divided into five experimental groups as follows: i) Dimethyl sulfoxide; ii) H₂O₂; iii) AsIV+H₂O₂; iv) AsIV+H₂O₂+5-hydroxydecan oate (5-HD); and v) nicorandil+H₂O₂. Cardiocyte survival was analyzed using an MTT assay. Lactate dehydrogenase (LDH) release was also assessed to evaluate the viability of the cells. Intracellular reactive oxygen species (ROS) were measured by 2,7-dichlorodihydrofluorescein diacetate staining. The apoptotic rate was measured by flow cytometry. Mitochondrial membrane potential (ΔΨm) and intracellular calcium were observed using a laser confocal microscopy system. The results indicated that AsIV promoted the survival of cardiocytes (P<0.05), attenuated LDH release (P<0.05), ROS production (P<0.01) and apoptosis (P<0.01), stabilized the ΔΨm and reduced intracellular calcium overload (P<0.01) compared with the H₂O₂ group. The mitochondrial adenosine triphosphate-sensitive potassium channel (mitoK<sub>ATP</sub>) inhibitor 5-HD was observed to partially reverse the protective effect of AsIV. Following treatment with 5-HD, the survival of cardiocytes was reduced (P<0.05), LDH release (P<0.01) and ROS production (P<0.05) were stimulated, ΔΨm and intracellular calcium change were increased (P<0.01) and apoptosis was increased (P<0.01) compared with the AsIV+H₂O₂ group. Thus, AsIV has potential for use in the suppression of apoptosis resulting from H₂O₂ exposure, and mitoK<sub>ATP</sub> activation may underlie this protective mechanism.

Introduction

Reperfusion is the most effective method of limiting acute myocardial ischemia necrosis. However, reperfusion may also be associated with a burst of reactive oxygen species (ROS) production and intracellular calcium overload (1-3). These dichotomic effects result in paradoxical cardiocyte dysfunction, a phenomenon termed myocardial ischemia reperfusion injury (MIRI). The role of mitochondria during MIRI is critical, as apoptosis is promoted by the mitochondrial pathway associated with the mitochondrial permeability transition (MPT). MPT pores (MPTPs) are located in the inner mitochondrial membrane, and when MIRI induces cellular dysfunction, including increased Ca<sup>2+</sup> concentrations and oxidative stress, mitochondria undergo swelling and become uncoupled due to the opening of MPTPs (4). This leads to matrix swelling, release of apoptotic signaling molecules and irreversible injury to the mitochondria (5). The role of the mitoK<sub>ATP</sub> channel in modulating cardiac mitochondrial function has been investigated previously (6,7). Wakiyama et al (8) confirmed that the opening of mitochondrial adenosine triphosphate-sensitive potassium channels (mitoK<sub>ATP</sub>) may reduce the release of cytochrome c, inhibit caspase-3 activation, stabilize the mitochondrial membrane potential (MMP) and inhibit apoptosis (8).

Astragaloside is one of the most common Traditional Chinese Medicines. It possesses multiple physiological and pharmacological functions, including a protective effect in the myocardium following ischemic injury. This effect may be associated with clearing oxygen free radicals or reducing blood viscosity (9,10). Notably, prior work has demonstrated that Astragalus injection (Huangqizhusheye) may activate the mitoK<sub>ATP</sub> and reduce MIRI (11). Astragaloside IV (AsIV) is an extract of the monomer astragaloside (Fig. 1). AsIV produces various effects, including protection against cerebral ischemia-reperfusion injury, and the attenuation of renal tubulointerstitial fibrosis and diabetes (12-14). Certain...
protective effects of AsIV on cardiovascular disease have also been suggested (15-19). In addition to providing cardioprotection during myocardial ischemia (18,19), AsIV has also been demonstrated to limit endothelial dysfunction induced by oxidative stress (15) and inhibit compensatory hypertrophy of myocardial cells (16). The results obtained in these previous studies provided the impetus to study the mechanism of AsIV protection during reperfusion.

In the current study, the protective role of mitoK<sub>ATP</sub> following AsIV treatment was investigated in cardiocytes. Oxidative stress in cardiocytes was stimulated by treating cultured cells with 0.2 mmol/l hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (20), resulting in calcium overload and damage to the MMP. These three factors may act separately, or interact with each other to cause damage to cellular structure, function and metabolism, and ultimately result in cell death. This type of injury simulates the pathogenesis of MIRI; thus, the present study used this model to analyze the effect of AsIV on MIRI and its underlying mechanisms.

Materials and methods

Cell culture and reagents. Primary rat neonatal cardiocytes were derived from 1-2-day-old Wistar rats (Experimental Animal Holding Facility of Jilin University, China). Briefly, the hearts were removed under aseptic conditions and the ventricles were homogenized in D-Hank's buffer. The tissue fragments were digested by stepwise exposure to 0.125% pancreatin (Gibco Life Technologies, Carlsbad, CA, USA). The dissociated cells were pre-plated for 90 min to remove fibroblasts, and the non-adherent cardiocytes were then plated at a density of 1x10<sup>6</sup> cells/mm<sup>2</sup>. Cells were cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (BHKT Clinical Reagent Co., Ltd, Beijing, China), and maintained at 37°C in an incubator with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. All animal studies were performed in accordance with the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee of Jilin University (Changchun, China).

2,4-Dichlorofluorescein diacetate (DCFH), Rhodamine 123 and A<sub>T</sub>TP were provided by Shanghai Chemical Factory (Beijing, China). The mitoK<sub>ATP</sub> inhibitor 5-hydroxydecanoate (5-HD) was also obtained from Sigma-Aldrich.

Peroxidation injury. To induce oxidative stress, cells were cultured in serum-free medium for 12 h when the cells were semiconfluent and beating synchronously. For the peroxidation challenge, the cells were cultured in medium with 0.2 mmol/l H<sub>2</sub>O<sub>2</sub> (Beijing Chemical Factory, Beijing, China) and maintained at 37°C for 24 h.

Experimental design. The present study utilized five experimental groups of cardiocytes as follows: i) the dimethyl sulfoxide (DMSO, Beijing Chemical Factory, Beijing, China) group, maintained in 0.1% DMSO; ii) the H<sub>2</sub>O<sub>2</sub> group, treated with 0.2 mmol/l H<sub>2</sub>O<sub>2</sub> for 24 h; iii) the AsIV+H<sub>2</sub>O<sub>2</sub> group, pretreated with 30 mg/l AsIV (provided by Academy of Chinese Medical Sciences of Jilin Province, Changchun, China) for 30 min prior to H<sub>2</sub>O<sub>2</sub> injury; iv) the AsIV+H<sub>2</sub>O<sub>2</sub>+5-HD group, pretreated with 50 µmol/l 5-HD for 5 min prior to the AsIV pretreatment; and v) the nicorandil (NIC; Changchun Dazheng International Trade Group Pharmaceutical Co., Ltd, Changchun, China)+H<sub>2</sub>O<sub>2</sub> group, pretreated with 120 mg/l NIC for 30 min prior to H<sub>2</sub>O<sub>2</sub> injury. The NIC+H<sub>2</sub>O<sub>2</sub> group was used as a positive control. For all AsIV treatments, a 0.1% AsIV stock solution was dissolved in DMSO.

Cardiocyte viability and lactate dehydrogenase (LDH) activity. Cardiocyte survival was assessed using an MTT assay. Briefly, cells were incubated with 200 µl medium in 96-well plates, 5 µl MTT stock solution (5 mg/ml) was then added to each well and the cells were incubated for a further 4 h. Blue formazan precipitate was produced from the cells by adding 100 µl DMSO and gently shaking, and the absorbance was measured at 570 nm using an A-5082 ELISA reader (Chengdu Taiyin Technology Co., Ltd., Chengdu, China). LDH release was measured using a GF-200 Semi Automatic Biochemical Analyzer (Shandong Gaomi Caihong Instruments Co., Ltd., Gaomi, China).

Analysis of ROS production. Intracellular ROS levels were analyzed using a flow cytometer with DCFH staining. DCFH was dissolved in ethanol (Beijing Chemical Factory, Beijing, China) to produce a 1 mmol/l stock solution. Cells were subsequently washed three times with phosphate-buffered saline (PBS) prior to the addition of DCFH (10 µM). Following a 10-min incubation in the dark, the cells were washed three times then resuspended in PBS. Fluorescence was measured using a fluorescence microplate reader at 488/525 nm (Gemini XPS; Shanghai Spectrum Instruments Co., Ltd., Shanghai, China).

Apoptosis analysis. The non-adherent myocytes were digested by treatment with 0.25% pancreatin for 10 min. The cells were then washed twice with PBS, and the percentage of apoptotic cells was determined with an Coulter Epics XL flow cytometer (Beckman Coulter, Brea, CA, USA) after double staining with the Annexin V-FITC apoptosis detection kit (Tianjin Sunge BioTech Co., Ltd, China). Annexin V was used as an apoptosis indicator and propidium iodide (PI) as a necrosis indicator. An<sup>PF</sup> represents viable apoptotic cells in the lower right quadrant.
Cytosolic calcium concentration, \([\text{Ca}^{2+}]_i\). Fluo-3 was used as a \(\text{Ca}^{2+}\) indicator during fluorescence imaging to assess \([\text{Ca}^{2+}]_i\). Changes in \([\text{Ca}^{2+}]_i\) were analyzed using a Fluoview FV500 confocal laser scanning microscope (Olympus Corporation, Tokyo, Japan). Cells in 24-well plates were washed with HEPES buffer and treated with Fluo-3/AM (10 µmol/l) for 40 min in the dark. Following removal of Fluo-3/AM, the cells were washed three times with HEPES, and fresh HEPES was added with the various drug treatments as described. Baseline fluorescence in normal cells was recorded for 1 min, then \(\text{H}_2\text{O}_2\) was added and the change in fluorescence was measured for 5 min. The results were analyzed using software which accompanied the confocal microscope. Alterations in the levels of green fluorescence were used to evaluate \([\text{Ca}^{2+}]_i\).

**MMP (ΔΨm).** Fluorescence imaging of ΔΨm was conducted using Rhodamine 123 as an indicator. Rhodamine 123 is a mitochondria-selective dye, which in a reaction driven by ΔΨm in normal polarized mitochondria, assembles into red fluorescence-emitting dimers forming J-aggregates. Changes in MMP were analyzed using the confocal microscope. Cells in 24-well plates were treated with Rhodamine 123 (5 µg/ml) for 10 min away from light. Following removal of Rhodamine 123, the cells were washed with PBS. The level of Rhodamine 123 was measured and analyzed with the Fluoview Viewer software, version 1.7a (Olympus Corporation).

**Statistics.** Data are expressed as the mean ± standard error of the mean. Statistical significance was calculated using one-way analysis of variance with Newman-Keuls post hoc test. \(P<0.05\) was considered to indicate a statistically significant difference.

**Results**

**Effect of AsIV on cardiocyte viability and the change in LDH activity.** Pretreatment with AsIV significantly increased cardiocyte viability compared with that of the \(\text{H}_2\text{O}_2\) group \((P<0.05)\), while pretreatment with 5-HD resulted in reduced viability \((P<0.05\) vs. the AsIV group) \((Fig. 2)\). As indicated in Fig. 3, cardiocyte damage resulting from \(\text{H}_2\text{O}_2\) exposure was reflected by increased LDH release \((P<0.01\) vs. the DMSO control group); which was reduced by AsIV pretreatment \((P<0.01\) vs. the \(\text{H}_2\text{O}_2\) group) and significantly increased in the 5-HD pretreatment group \((P<0.05\) vs. the AsIV group). These results indicated that AsIV may protect cardiocytes against \(\text{H}_2\text{O}_2\) injury, while the mitoK\(_{\text{ATP}}\) inhibitor 5-HD may partially reverse this effect.

AsIV alters oxidative stress and \([\text{Ca}^{2+}]_i\). Elevated levels of ROS may contribute to ischemia-reperfusion injury. Therefore, the present study evaluated whether AsIV-mediated cardioprotection may be partially attributed to a reduction in oxidative stress. ROS generation was assessed by DCFH fluorescence. The results indicated that \(\text{H}_2\text{O}_2\) induced significant ROS generation in cardiocytes compared with the DMSO control group \((P<0.01)\) \((Fig. 3)\), which was reduced following AsIV treatment \((P<0.05\) vs. the \(\text{H}_2\text{O}_2\) group). This protective effect was significantly attenuated by 5-HD pretreatment \((P<0.05)\). These results indicate that AsIV may protect cardiocytes against \(\text{H}_2\text{O}_2\) injury by reducing oxidative stress; and this effect may be associated with the mitoK\(_{\text{ATP}}\).

\(\text{Ca}^{2+}\) overload is a key contributor to the mitochondrial permeability transition leading to ischemia-reperfusion injury. As displayed in Fig. 4, AsIV-pretreated cells presented significantly lower \([\text{Ca}^{2+}]_i\) compared with that of the \(\text{H}_2\text{O}_2\) group \((P<0.01)\). 5-HD pretreatment prior to AsIV exposure resulted in significantly higher \([\text{Ca}^{2+}]_i\) compared with that of the AsIV group \((P<0.01)\). These results indicated that AsIV may relieve \(\text{Ca}^{2+}\) overload, an effect which is also associated with the mitoK\(_{\text{ATP}}\).

**Changes in MMP.** MPTP opening may be critical for the transition from reversible to irreversible myocardial ischemia-reperfusion injury. Therefore, the present study investigated MPTP dynamics in cardiocytes using Rhodamine 123. The MMP was \((93.80±19.53)\) 30 min subsequent to AsIV treatment, which was significantly higher than that in the \(\text{H}_2\text{O}_2\) group \((P<0.01)\) \((Fig. 5)\). 5-HD pretreatment prior to AsIV led to an MMP that was significantly lower than that of the AsIV group \((P<0.01)\). These results demonstrated that AsIV may protect cardiocytes by stabilizing the MMP, and this effect may be associated with the mitoK\(_{\text{ATP}}\).

**Changes in the rate of apoptosis.** The effect of AsIV on cell apoptosis was analyzed by measuring Annexin V positivity using flow cytometry. Pretreatment with AsIV led to significantly reduced Annexin V-positivity compared with the \(\text{H}_2\text{O}_2\).
By contrast, pretreatment with 5-HD resulted in a significant increase in the number of Annexin V-positive cells compared with the As IV group (P<0.01) (Fig. 6). These results demonstrated that As IV treatment may reduce apoptosis, and this may be associated with the mitoK<sub>ATP</sub>.

**Discussion**

The generation of ROS leads to damage to the cellular membrane, and is able to evoke calcium overload by raising membrane permeability, resulting in an inflow of calcium ions. Calcium overload may activate calcium-dependent proteinase, which catalyzes the conversion of xanthine dehydrogenase to xanthine oxidase (XO). XO promotes xanthine decomposition into uric acid with concomitant excess oxygen free radical generation. Mitochondrial Ca<sup>2+</sup> overload, coupled with a high intracytoplasmic ROS burden, promotes the opening of the MPTPs, which induces the release of calcium from mitochondria resulting in mitochondrial swelling or failure. The combination of increased ROS, Ca<sup>2+</sup> overload and mitochondrial injury is a notable cause of cardiocyte apoptosis.

The results of the current study demonstrated that As IV increased cardiocyte viability and reduced LDH release. Additionally, pretreatment with As IV significantly reduced apoptosis, which demonstrated that As IV was able to protect cardiocytes from H<sub>2</sub>O<sub>2</sub> injury and inhibit apoptosis.

As IV-mediated attenuation of ROS generation and Ca<sup>2+</sup> overload in H<sub>2</sub>O<sub>2</sub>-damaged cardiocytes demonstrated that
the protective effects of AsIV are dependent on antioxidant activity and reducing the intracellular calcium overload. These effects may protect cardiocytes by attenuating damage to mitochondrial function.

Mitochondrial activity is required for efficient function of the cardiovascular system. In response to cardiovascular injury, mitochondrial dysfunction may result in apoptosis and necrosis (21). A change in mitochondrial permeability is considered the primary event in the cell apoptosis cascade (22-24). The fluctuations in MMP result in cytochrome c release, which can initiate caspase-9 and -3 activation, and subsequent apoptosis (25). In the present study, AsIV was observed to protect against cell death by modulating mitochondrial membrane permeability, which may attenuate the release of cytochrome c and reduce cardiocyte apoptosis. MitoK\textsubscript{ATP} channels are located in the mitochondrial inner membrane, and the opening of these channels has been suggested to be protective against excessive mitochondrial Ca\textsuperscript{2+} accumulation, as mitoK\textsubscript{ATP} opening leads to depolarization, which reduces the driving force responsible for mitochondrial Ca\textsuperscript{2+} uptake (26). MitoK\textsubscript{ATP} opening also regulates ROS generation; in early ischemia (30 min), mitoK\textsubscript{ATP} opening can increase the production of ROS to begin cardiocyte protection by preconditioning. However, during late ischemia (24 h) or reperfusion, mitoK\textsubscript{ATP} opening may reduce the production of ROS to reduce injury (27). Previous studies have indicated that mitoK\textsubscript{ATP} serves an important function in the protection against ischemia-reperfusion injury by the mitoK\textsubscript{ATP} opening agent, diazoxide, using an siRNA method and mitoK\textsubscript{ATP} blocker 5-HD (28,29). Wakiyama et al (8) confirmed that mitoK\textsubscript{ATP} opening may attenuate the release of cytochrome c, inhibit caspase-3 release, stabilize the MMP and inhibit apoptosis. Soeding et al (30) also demonstrated that levsimendan, a calcium sensitizer, preserves the contractile responsiveness of hypoxic human myocardium via mitoK\textsubscript{ATP}, and potential pERK1/2 activation.

To investigate the link between AsIV and the mitoK\textsubscript{ATP}, the present study examined the effect of 5-HD on the effects of AsIV. It was observed that pretreatment with 50 µmol/l 5-HD, (a specific mitoK\textsubscript{ATP} blocker) partially abrogated the protective effect of AsIV in the cardiocytes. 5-HD led to a reduction in viability and MMP, an increase in the levels of LDH and apoptosis and an increase in calcium overload, compared with the AsIV group. These data indicate that AsIV may protect cardiocytes from H\textsubscript{2}O\textsubscript{2} injury through activating mitoK\textsubscript{ATP}. This concentration of 5-HD had no effect on cardiocytes alone (data not shown). It was also observed that AsIV produced a similar protective effect to the drug nicorandil, a mitoK\textsubscript{ATP} activator.

Based on these findings, it was concluded that the opening of mitoK\textsubscript{ATP} may be the principal mechanism through which AsIV protects cardiocytes from H\textsubscript{2}O\textsubscript{2} injury. AsIV may inhibit apoptosis in cardiocytes via several mechanisms: i) AsIV inhibits the initiation of apoptosis by reducing the formation of mitochondria-related caspases (25). ii) AsIV may activate the mitochondrial permeability transition (MPT) in cardiocytes, which is an opening of the mitochondrial inner membrane, leading to the release of cytochrome c and the activation of caspase-9 and caspase-3 (25). iii) AsIV may activate the p38 MAPK pathway, leading to the activation of caspase-3 and the inhibition of anti-apoptotic proteins, such as Bcl-2 (25). iv) AsIV may activate the nuclear factor-κB (NF-κB) pathway, leading to the activation of caspase-3 and the inhibition of anti-apoptotic proteins, such as Bcl-2 (25). v) AsIV may activate the Akt pathway, leading to the inhibition of the mitochondrial permeability transition pore (MPTP), which is associated with the opening of the mitochondrial inner membrane, leading to the release of cytochrome c and the activation of caspase-3 (25). vi) AsIV may activate the AMPK pathway, leading to the activation of caspase-3 and the inhibition of anti-apoptotic proteins, such as Bcl-2 (25). vii) AsIV may activate the PI3K/Akt pathway, leading to the activation of caspase-3 and the inhibition of anti-apoptotic proteins, such as Bcl-2 (25).

Figure 6. Effect of AsIV on apoptosis of cardiocytes damaged by H\textsubscript{2}O\textsubscript{2}. (A) Annexin V was used as an apoptosis indicator and PI as necrosis indicator. An+PI represents viable apoptotic cells in the lower right quadrant. (B) Quantification of apoptotic staining (n=3). ***P<0.001 vs. the DMSO group, **P<0.01 vs. the H\textsubscript{2}O\textsubscript{2} group, ∆∆P<0.01 vs. the AsIV+H\textsubscript{2}O\textsubscript{2} group. AsIV, astragaloside IV; H\textsubscript{2}O\textsubscript{2}, hydrogen peroxide; PI, propidium iodide; An, annexin V; DMSO, dimethyl sulfoxide; FITC, fluorescein isothiocyanate.
of ROS and intracellular calcium overload; ii) AsIV inhibits the opening of MPTPs, which may reduce the release of apoptosis-inducing proteins, including cytochrome c, Smac and AIF; and iii) mitoK<sub>ATP</sub> opening may facilitate the signal transduction required for protection by AsIV. Further studies are required to elucidate whether other trigger factors underlie the protective effects of AsIV. Additionally, the detailed downstream mediators of mitoK<sub>ATP</sub> require clarification.

Acknowledgements

This study was supported by the Science and Technology Department of Jilin Province (grant no. YYZX201260).

References